Kaylee Baker
Primary Care · Philadelphia, PANPI 1003447368
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by AstraZeneca at 32.6% of the total. Among primary care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $87.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Cvrx, Inc.$2K
- Impulse Dynamics (USA) Inc.$934
- Medtronic$400
- Inari Medical, Inc.$238
- Alnylam Pharmaceuticals Inc.$236
- plus $1K from 10 others
What the payments were for
- Consulting fees$1,50022%
- Travel & lodging$1,22918%
- Food & beverage$4,08460%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $2,218 |
| Cvrx, Inc. | 12 | $1,776 |
| Impulse Dynamics (USA) Inc. | 25 | $934 |
| Medtronic | 5 | $400 |
| Inari Medical, Inc. | 1 | $238 |
| Alnylam Pharmaceuticals Inc. | 2 | $236 |
| Abbott | 3 | $213 |
| Amgen | 2 | $163 |
| Kestra Medical Technology Services, Inc. | 5 | $138 |
| Merck | 2 | $129 |
| Bridgebio Pharma, Inc. | 1 | $117 |
| Boehringer Ingelheim | 1 | $94 |
| Novartis | 4 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $44 |
| Boston Scientific | 1 | $25 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$1,462
- WAINUA$750
- OPTIMIZER$366
- COREVALVE EVOLUT R$255
- FLOWTRIEVER CATHETER, S$238
- CT THROMBECTOMY SYSTEM KIT$238
- AMVUTTRA$236
- VERQUVO$224
- Repatha$139
- NAVITOR$129
- FARXIGA$120
- Attruby$117
- ANDEXXA$116
How this compares
$6,812 in reported general payments places this provider in the 95th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 432 | $11,781,929 |
| VyndaqelTafamidis Meglumine | 70 | $1,838,022 |
| EntrestoSacubitril/Valsartan | 92 | $90,930 |
| FarxigaDapagliflozin Propanediol | 54 | $60,770 |
| JardianceEmpagliflozin | 45 | $58,257 |
| EliquisApixaban | 47 | $52,792 |
| Repatha SureclickEvolocumab | 20 | $10,811 |
| Atorvastatin Calcium | 99 | $1,496 |
| Torsemide | 47 | $1,437 |
| Valsartan | 27 | $1,245 |
| Potassium Chloride | 42 | $967 |
| Metoprolol Succinate | 54 | $880 |
| Spironolactone | 97 | $753 |
| Ezetimibe | 14 | $627 |
| Rosuvastatin Calcium | 27 | $446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $72 | $90,93092 claims |
| AstraZenecaFarxiga | $2,218 | $60,77054 claims |
| Boehringer IngelheimJardiance | $94 | $58,25745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 primary care providers in Pennsylvania.
Other primary care in Philadelphia
- Teresa GiamboyPhiladelphia$21K
- Galyna VorokhibPhiladelphia$12K
- Jarrell HillPhiladelphia$6K
- Valerie DailyPhiladelphia$4K
- Adunni WardPhiladelphia$3K
- Avigad FeldmanPhiladelphia$3K
- Peggy DerussoPhiladelphia$3K
- Jennifer MalloyPhiladelphia$3K
- Emily MateyPhiladelphia$2K
- Kersten ReiderMount Penn$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.